Myelodysplastic Syndromes (MDS)

Dr. George is an a Clinician scientist involved in the management of patients with haematological disorders for the past 20 years. He completed my sub-specialty training (DM) in Clinical Haematology in 2002 at CMC Vellore under the guidance of Dr. Mammen Chandy. His thesis for DM in Clinical Haematology was studying the Profile of Infections in patients undergoing stem cell transplantation. After completion of his training, he has been involved in setting up protocols for the diagnosis and management of various infections following chemotherapy and stem cell transplantation. His keen interest

Dr. Cutler received his MD from McGill University, Montreal, Canada. He subsequently received his MPH from the Harvard school of Public Health. He completed postgraduate training in Internal Medicine at Royal Victoria Hospital, Montreal, followed by a fellowship in Hematology/Oncology at DFCI. In 2002, he joined DFCI, where he currently is a member of the Hematologic Malignancies staff.

Dr. M. Sitki Copur is a nationally known medical oncologist. He is an adjunct faculty professor at the University of Nebraska Medical Center Department of Internal Medicine Division of Hematology/Oncology. He graduated from medical school at Hacettepe University in Ankara, Turkey. He served an Internal Medicine Residency, also in Turkey, before completing an internship and residency, both at Chicago Medical School in Chicago. His medical oncology fellowship was at the National Cancer Institute in Bethesda, Maryland. He is board certified in Internal Medicine and Medical Oncology, and serves on

Ehab Atallah, MD, is a Professor of Medicine and Section Head of hematological malignancies in the Medical College of Wisconsin Division of Hematology and Oncology, specializing in leukemia and myelodysplastic syndromes at Froedtert Hospital. He graduated from Cairo University School of Medicine in 1994, then completed an internal medicine residency in the Cleveland Clinic Health System and a fellowship in hematology/oncology at the Karmanos Cancer Center in Detroit, Michigan, where he also served as Chief Fellow. He then went on to complete a leukemia fellowship at M.D. Anderson Cancer Center

Dr. Erba entered medical school for the sole purpose of learning more about human diseases, so that he could focus his laboratory efforts on improving the human condition. However, he was surprised to find himself drawn to clinical care. He cares for people afflicted by acute leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. In this role, Dr. Erba has had the privilege of treating people facing life-threatening illnesses. He strives to gain the trust of each of his patients, so that he can help them make difficult treatment decisions. He engages in clinical research

Dr. DiNardo is a clinical researcher with a specialized focus on prognostication and personalized therapeutics for patients with myeloid malignancies. She has completed formal training in epidemiology and biostatistics, with a Master’s of Science in Clinical Epidemiology obtained in June 2012. Her thesis involved an analysis of isocitrate dehydrogenase (IDH) mutations, serum 2-hydroxyglutarate (2HG) levels, and patient outcomes in AML, performed in collaboration with the Eastern Cooperative Oncology Group (ECOG). Dr. DiNardo is the primary investigator of multiple novel IDH1 or IDH2-targeted